AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01609049
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of treatment will be according to local recommendation under local labeling.
Trial: NCT01609049
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
Trial: NCT03735875
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03735875
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01177943
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally, once.
Trial: NCT00958282
Drug: lisdexamfetamine/Behavior Therapy
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04589260
Drug: TD-1058
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug to be administered by oral inhalation
Trial: NCT01059955
Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437)
RxNorm normalized name: dexamethasone phosphate Ophthalmic Ointment
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
Trial: NCT01059955
Drug: Dexamethasone phosphate ophthalmic solution
RxNorm normalized name: dexamethasone phosphate Ophthalmic Solution
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
Trial: NCT02514083
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 420mg PO daily for the duration of the study.
Trial: NCT02514083
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
Trial: NCT00381017
Drug: Peg interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04116073
Drug: INCMGA00012 (PD-1 antibody)
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~2. Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)
Trial: NCT02557269
Drug: Xylometazoline - intranasal application
RxNorm normalized name: XYLOMETAZOLINE
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied as needed up to 5 consecutive days when prominent congestion
Trial: NCT02557269
Drug: Azelastine - intranasal application
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied as needed when prominent symptom is rhinorrhea
Trial: NCT02557269
Drug: Mometasone furoate - intranasal application
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
Trial: NCT02557269
Drug: Hydroxyl-propyl-methyl cellulose powder - intranasal application
RxNorm normalized name: Hydroxy Propyl Methyl Cellulose
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied intranasally immediately after every application other intranasal formulation
Trial: NCT02557269
Drug: Bilastine 20 mg
RxNorm normalized name: Bilastine 20 mg oral tablet
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1 tablet per os - as needed
Trial: NCT02467504
Drug: hrIL-2 active
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
Trial: NCT02467504
Drug: MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (oral administration)
Trial: NCT02467504
Drug: Loxoprofen
RxNorm normalized name: Loxoprofen
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Loxoprofen (oral administration)
Trial: NCT00490815
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg fluocinolone acetonide intravitreal insert
Trial: NCT00490815
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2 mg fluocinolone acetonide intravitreal insert
Trial: NCT03846310
Drug: Etrumadenant
RxNorm normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrumadenant is an A2aR and A2bR antagonist
Trial: NCT03846310
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Trial: NCT03846310
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered as part of standard chemotherapy regimen
Trial: NCT03846310
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed administered as part of standard chemotherapy regimen
Trial: NCT03846310
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
Trial: NCT01432470
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
Trial: NCT03190304
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
Trial: NCT02815670
Drug: Idarucizumab
RxNorm normalized name: Idarucizumab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03674385
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
Trial: NCT03674385
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: is a medication used to treat infertility in women who do not ovulate
Trial: NCT00100711
Drug: Motexafin Gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01728194
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg target dose for 12 weeks
Trial: NCT02609919
Drug: Gadoteric Acid
RxNorm normalized name: Gadoteric acid
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI Contrast Agent
Trial: NCT03059134
Drug: Mirabegron 25mg
RxNorm normalized name: MIRABEGRON 25MG SA TAB
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
Trial: NCT01159665
Drug: ocriplasmin
RxNorm normalized name: Ocriplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 125µg ocriplasmin intravitreal injection
Trial: NCT06790303
Drug: Feladilimab
RxNorm normalized name: Feladilimab
DrugBank: Feladilimab (DB16415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feladilimab will be administered.
Trial: NCT06790303
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab will be administered
Trial: NCT03778281
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
Trial: NCT03378219
Drug: Sarilumab SAR153191 (REGN88)
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:injection Route of administration: subcutaneous
Trial: NCT00016068
Drug: ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00016068
Drug: valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01843829
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01843829
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01843829
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00106860
Drug: a benzodiazepine drug
RxNorm normalized name: 8-chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01883362
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
Trial: NCT00277862
Drug: Pegylated IFN- alpha 2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00277862
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04301557
Drug: PD-1 Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
Trial: NCT04301557
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
Trial: NCT01349816
Drug: PT003
RxNorm normalized name: Tiotropium bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PT003 MDI administered as two puffs BID for 7 days
Trial: NCT01349816
Drug: PT001
RxNorm normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PT001 MDI administered as two puffs BID for 7 days
Trial: NCT01349816
Drug: PT005
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PT005 MDI administered as two puffs BID for 7 days
Trial: NCT02569996
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
Trial: NCT01766024
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
Trial: NCT02312934
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
Trial: NCT00199381
Drug: Istradefylline
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Trial: NCT01940952
Drug: Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
RxNorm normalized name: donepezil hydrochloride 5 MG
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01940952
Drug: Placebo + Donepezil 5mg or 10mg
RxNorm normalized name: donepezil hydrochloride 10 MG
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01940952
Drug: Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
RxNorm normalized name: donepezil hydrochloride 5 MG
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01586364
Drug: Ospemifene 60Mg Oral Tablet
RxNorm normalized name: ospemifene 60 MG
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02173158
Drug: lomitapide
RxNorm normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03740724
Drug: veledimex
RxNorm normalized name: Veledimex
DrugBank: Veledimex (DB12170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
Trial: NCT01295814
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Trial: NCT00988910
Drug: EE30-DRSP (Yasmin, BAY86-5131)
RxNorm normalized name: DRSP
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DRSP-containing combined oral contraceptives according to the normal routine praxis
Trial: NCT00988910
Drug: Other combined oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other combined oral contraceptives according to the normal routine praxis
Trial: NCT01157819
Drug: 0.3% Ciprofloxacin Ear Drops
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 gtt b.i.d. for 7 days.
Trial: NCT01817218
Drug: Platelet Rich Plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02661789
Drug: Goserelin 3.6 mg implant
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacologically induced biphasic sex-steroid hormone fluctuation
Trial: NCT00411229
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion, 130mg/m²
Trial: NCT01687985
Drug: BLI801 laxative - low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BLI801 laxative - oral solution
Trial: NCT01687985
Drug: BLI801 laxative - high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI801 laxative - oral solution
Trial: NCT02911285
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200mg bid (2400mg/day)
Trial: NCT01397409
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab 0.5 mg given by intravitreal injection.
Trial: NCT02511691
Drug: 18F-PSS232
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic PET Tracer
Trial: NCT04427306
Drug: T-Vec
RxNorm normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
Trial: NCT02218424
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04275024
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
Trial: NCT04275024
Drug: PSORI-CM01 Granule
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
Trial: NCT01013805
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
Trial: NCT02427412
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
Trial: NCT02427412
Drug: Saline water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of Saline water injected into the knee capsula at the end of surgery.
Trial: NCT02427412
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
Trial: NCT00702637
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01265511
Drug: SCY-635
RxNorm normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCY-635 tablets, 300 mg bid for 28 days
Trial: NCT01265511
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 ug prefilled syringe given once per week for up to 48 weeks
Trial: NCT01265511
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets given bid for up to 48 weeks
Trial: NCT02993731
Drug: Napabucasin
RxNorm normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
Trial: NCT02993731
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Trial: NCT02993731
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Trial: NCT03651011
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
Trial: NCT02760420
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Trial: NCT00758667
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
Trial: NCT00574197
Drug: Mycophenolate Sodium
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1440mg/day (720mg by mouth, twice a day)
Trial: NCT00211133
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no